# US 2006/0069070 A1 · Treatment of fibrosis using FXR ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0069070 A1
- Document ID: US20060069070A1
- Status: Published application
- Kind: A1
- Application number: 11/081,002
- Filed: 2005-03-14
- Published: 2006-03-30
- Earliest claimed: 2004-03-12
- Assignees: Intercept Pharmaceuticals, Inc.
- Inventors: Stefano Fiorucci; Roberto Pellicciari; Mark Pruzanski
- Web page: https://patentgrep.com/patent/US20060069070A1

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 17/04: Antipruritics
- A61P 31/10: Antimycotics
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

## Claims

### Claim 1

A method for inhibiting fibrosis in a subject not suffering from a cholestatic condition, the method comprising the step of administering to the subject an effective amount of a ligand specific for the farnesoid X receptor (FXR), wherein the fibrosis to be inhibited occurs in an organ where FXR is expressed, with the proviso that the ligand is not chenodeoxyxholic acid (CDCA) or ursodeoxycholic acid (UDCA).

### Claim 2

A method for inhibiting fibrosis in a subject not suffering from a cholestatic condition, the method comprising the step of administering to the subject an effective amount of a ligand specific for the farnesoid X receptor (FXR), wherein the fibrosis to be inhibited occurs in an organ where FXR is expressed, and wherein the ligand has an EC50 no greater than 5 μM in a cell-free FXR assay or in a cell-based FXR transactivation assay.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ligand has an EC50 no greater than 1 μM.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the cholestatic condition is defined as having abnormally elevated serum levels of alkaline phosphatase, -y-glutamyl transpeptidase (GGT), and 5′ nucleotidase.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cholestatic condition is further defined as presenting with at least one clinical symptom.

### Claim 6 (depends on 5)

The method of claim 5, wherein the symptom is itching (pruritus).

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the fibrosis is selected from the group consisting of liver fibrosis, kidney fibrosis, and intestinal fibrosis.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2, wherein the cholestatic condition is selected from the group consisting of primary biliary cirrhosis, primary sclerosing cholangitis, drug-induced cholestasis, hereditary cholestasis, and intrahepatic cholestasis of pregnancy.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject is not suffering from a cholestatic condition associated with a disease or condition selected from the group consisting of primary liver and biliary cancer, metastatic cancer, sepsis, chronic total parenteral nutrition, cystic fibrosis, and granulomatous liver disease.

### Claim 10 (depends on 1, 2)

The method of claim 1 or 2, wherein the ligand is selected from the group consisting of 6ECDCA, tauro-6ECDCA, 6EUDCA, GW4064, 6α-MeCDCA, 6α-PrCDCA, fexaramine, and guggulsterone.

### Claim 11 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject has liver fibrosis associated with a disease selected from the group consisting of hepatitis B; hepatitis C; parasitic liver diseases; post-transplant bacterial, viral and fungal infections; alcoholic liver disease (ALD); non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); liver diseases induced by methotrexate, isoniazid, oxyphenistatin, methyldopa, chlorpromazine, tolbutamide, or amiodarone; autoimmune hepatitis; sarcoidosis; Wilson's disease; hemochromatosis; Gaucher's disease; types III, IV, VI, IX and X glycogen storage diseases; α1-antitrypsin deficiency; Zellweger syndrome; tyrosinemia; fructosemia; galactosemia; vascular derangement associated with Budd-Chiari syndrome, veno-occlusive disease, or portal vein thrombosis; and congenital hepatic fibrosis.

### Claim 12 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject has intestinal fibrosis associated with a disease selected from the group consisting of Crohn's disease, ulcerative colitis, post-radiation colitis, and microscopic colitis.

### Claim 13 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject has renal fibrosis associated with a disease selected from the group consisting of diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, and polycystic kidney disease.

### Claim 14

A kit for inhibiting fibrosis in a subject not suffering from a cholestatic condition, wherein the fibrosis to be inhibited occurs in an organ where farnesoid X receptor (FXR) is expressed, the kit comprising:
an effective amount of a ligand specific for FXR, with the proviso that the ligand is not chenodeoxyxholic acid (CDCA) or ursodeoxycholic acid (UDCA); and,
an instructional material teaching the indications, dosage, and schedule of administration of the ligand to the patient.

### Claim 15

A kit for inhibiting fibrosis in a subject not suffering from a cholestatic condition, wherein the fibrosis to be inhibited occurs in an organ where farnesoid X receptor (FXR) is expressed, the kit comprising:
an effective amount of a ligand specific for FXR, wherein the ligand has an EC50 no greater than 5 μM in a cell-free FXR assay or in a cell-based FXR transactivation assay; and,
an instructional material teaching the indications, dosage, and schedule of administration of the ligand to the patient.

### Claim 16 (depends on 15)

The kit of claim 15, wherein the ligand has an EC50 no greater than 1 μM.

### Claim 17 (depends on 14, 15)

The kit of claim 14 or 15, wherein the fibrosis is selected from the group consisting of liver fibrosis, kidney fibrosis, and intestinal fibrosis.

### Claim 18 (depends on 14, 15)

The kit of claim 14 or 15, wherein the ligand is selected from the group consisting of 6ECDCA, tauro-6ECDCA, 6EUDCA, GW4064, 6α-MeCDCA, 6α-PrCDCA, fexaramine, and guggulsterone.

### Claim 19 (depends on 14, 15)

The kit of claim 14 or 15, wherein the ligand is presented in a pharmaceutical composition suitable for oral or intravenous administration.
